Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

FDA Says Newer Paclitaxel Data Is ‘Comforting’ but Limited

News Daily News

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

L.A. McKeown

January 12, 2021

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Daily News

Potential Benefits of Drug-Coated Balloons for Infrapopliteal Disease Remain Uncertain

Todd Neale

April 28, 2016

Advertisement

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

FDA’s First Take on New Paclitaxel Concerns in CLI

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Potential Benefits of Drug-Coated Balloons for Infrapopliteal Disease Remain Uncertain

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content